Senapati, Jayastu
Muftuoglu, Muharrem
Ishizawa, Jo
Abbas, Hussein A. http://orcid.org/0000-0003-2946-3562
Loghavi, Sanam http://orcid.org/0000-0001-8980-3202
Borthakur, Gautam http://orcid.org/0000-0001-7679-6453
Yilmaz, Musa http://orcid.org/0000-0002-4498-4895
Issa, Ghayas C. http://orcid.org/0000-0002-4339-8683
Dara, Samuel I.
Basyal, Mahesh
Li, Li
Naqvi, Kiran
Pourebrahim, Rasoul
Jabbour, Elias J. http://orcid.org/0000-0003-4465-6119
Kornblau, Steven M. http://orcid.org/0000-0002-5990-9548
Short, Nicholas J. http://orcid.org/0000-0002-2983-2738
Pemmaraju, Naveen http://orcid.org/0000-0002-1670-6513
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Ravandi, Farhad http://orcid.org/0000-0002-7621-377X
Khoury, Joseph http://orcid.org/0000-0003-2621-3584
Daver, Naval http://orcid.org/0000-0001-7103-373X
Kantarjian, Hagop M. http://orcid.org/0000-0002-1908-3307
Andreeff, Michael http://orcid.org/0000-0002-1144-1958
DiNardo, Courtney D. http://orcid.org/0000-0001-9003-0390
Article History
Received: 30 March 2023
Revised: 2 June 2023
Accepted: 13 June 2023
First Online: 29 June 2023
Conflict of interest
: EJ: reports research grants from Abbvie, Adaptive Biotechnologies, Amgen, Pfizer, and Takeda; and consultancy fees from Abbvie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Genentech, Incyte, Novartis, Pfizer, and Takeda. NJS reports research grants from Takeda Oncology, Astellas Pharma, Xencor, and Stemline Therapeutics; consultancy fees from Pfizer and Jazz Pharmaceuticals; and honoraria from Novartis, Amgen, Sanofi, and BeiGene. NP reports research grants from Novartis, Stemline Therapeutics, Samus Therapeutics, Abbvie, Cellectics, Affymetrix/Thermo Fisher Scientific, Daiichi Sankyo, Plexxikon, MustangBio, honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, Abbvie, MustangBio, Roche Molecular Diagnostics, Blueprint Medicines, DAVA Pharmaceuticals, Springer Science+Business Media LLC, Aptitude Health, NeoPharm, CareDX, Consulting or advisory role in Blueprint Medicines, Pacylex Pharmaceuticals Inc., Immunogen, Mristol Myers Squibb, Clearview Healthcare Partners, Astellas Pharma US Inc., Protagonist Therapeutics, Triptych Health Partners, CTI BioPharma Corp and Travel/accommodation expenses from Stemline Therapeutics, Celgene, Abbvie, DAVA oncology, MustangBio. ND: reports research funding from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi-Sankyo, Abbvie, Hanmi, Trovagene, FATE therapeutics, Amgen, Novimmune, Glycomimetics, Trillium, and ImmunoGen; and served in a consulting or advisory role for Daiichi-Sankyo, Bristol-Myers Squibb, Arog, Pfizer, Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, Shattuck labs, and Agios. HK: reports research grants from AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Daiichi-Sankyo, Immunogen, Jazz, Novartis, and Pfizer; and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, Astra Zeneca, Ipsen, Pharmaceuticals, KAHR Medical, NOVA Research, Novartis, Pfizer, Precision Biosciences, and Taiho Pharmaceutical Canada. All other authors declare no competing interests. MA: reports research funding from AstraZeneca, Amgen, Daiichi Sankyo, Jazz, GlycoMimetics; consultancy fees from Amgen, AstraZeneca, Daiichi Sankyo, Syndax, GlycoMimetics, Oncoceutics, and Aptose; and holds stock from Reata, Oncoceutics/Chimerix and Aptose. CDD: reports research grants from Abbvie, Agios/Servier, Astex, Calithera, Celgene/BMS, Cleave, Daiichi-Sankyo, ImmuneOnc, Loxo; honoraria/consulting fees from Abbvie, Agios/Servier, Astellas, Celgene/BMS, Cleave, Foghorn, Genentech, Novartis, Notable Labs, Takeda.
: The trial was approved by the Institutional Review Board.